In the CML group, NF-κB2 was 2.110-fold upregulated while NF-κB1 and Rel were downregulated 1.056-fold and 1.239-fold, respectively. The gene discussed is REL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.